Saturday 17 October 2026
Export ENSC’s income statement to Excel — free account
Ensysce Biosciences, Inc.
ENSC Healthcare Biotechnology
Ensysce Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.1 million, down 2.75% from fiscal 2024. In the quarter to June 2026, revenue fell 15.1%, EPS grew 74.7% and free cash flow grew 27.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.52
0.08
−13.33%
Follow ENSC
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.52 | 0.46 | 0.78 | 0.84 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.67) | (1.54) | (1.05) | (1.93) | |
P/B ratio |
7.82 | 0.82 | 0.00 | 0.00 | |
Price to Tangible BV |
7.82 | 0.82 | 0.00 | 0.00 | |
EV/Sales |
1.33 | (0.23) | 0.80 | 0.87 | |
EV/EBITDA |
0.00 | 0.11 | 0.00 | 0.00 | |
EV/Operating CF |
(0.85) | 0.15 | (0.39) | (0.44) | |
EV/FCF |
(0.85) | 0.15 | (0.39) | (0.44) | |
Quick Ratio |
0.73 | 1.04 | 0.26 | 0.27 | |
Current Ratio |
1.27 | 1.59 | 0.71 | 0.70 | |
Net Debt/EBITDA |
0.45 | 1.55 | 0.21 | 0.26 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.71 | 0.78 | 1.39 | 1.06 | |
Operating CF/Net income |
0.50 | 0.55 | 0.98 | 0.76 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(584.55) | (515.15) | (913.38) | (8,588.00) | |
Research and Development Expense of Revenue |
599.25% | 191.95% | 348.27% | 212.30% | |
Selling, General and Administrative Expense of Revenue |
259.44% | 55.84% | 122.40% | 108.99% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
(10.20%) | 1.30% | 0.91% | 0.16% | |
Graham Net Nets |
0.09 | 1.14 | (0.22) | (0.32) | |
Graham Number |
0.00 | 0.00 | 2.72 | 2.30 | |
Earnings Yield |
(268.78%) | (458.70%) | (620.37%) | (951.72%) | |
Free Cash Flow Yield |
(102.99%) | (331.84%) | (259.94%) | (234.24%) | |
Revenue per Share |
0.17 | 0.74 | 0.14 | 0.09 | |
Operating CF per Share |
(0.65) | (0.60) | (0.51) | (0.15) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.65) | (0.60) | (0.51) | (0.15) | |
Cash per Share |
0.58 | 1.69 | 0.11 | 0.05 | |
Shareholders Equity per Share |
0.30 | 1.13 | (0.10) | (0.09) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.30 | 1.13 | (0.10) | (0.09) | |
Free Cash Flow |
(1.87) | (1.53) | (3.50) | (1.96) | |
Working Capital |
0.62 | 2.68 | (0.83) | (1.22) | |
Capital Expenditures |
— | (0.12) | — | — | |
Net Current Asset Value |
0.62 | 2.68 | (0.83) | (1.22) | |
EV/EBIT |
0.00 | 0.11 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.89 | 0.27 | — | 0.22 | |
Average Payables |
1.22 | 2.31 | 1.11 | 1.51 | |
Average Assets |
6.28 | 6.52 | 3.39 | 4.27 | |
Average Common Equity |
3.73 | 3.13 | 1.03 | 0.97 |
Columns are period end dates